Aura Biosciences cierra una ronda Serie D de $40M liderada por Medicxi, acuden Ysios, Advent Life, Aris Bioscience, Chiesi, ColumbusVP y Lundbeckfonden
02/04/2019 Nota de prensa AURA BIOSCIENCES CIERRA UNA RONDA SERIE D DE $40 MILLONES LIDERADA POR MEDICXI, ACUDEN YSIOS CAPITAL, ADVENT LIFE SCIENCES, ARIS BIOSCIENCE, CHIESI, COLUMBUSVP Y LUNDBECKFONDEN. Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New…